@hotcongo @Boffin99Actually, there are several subsets of...

@hotcongo @Boffin99

Actually, there are several subsets of cancers that have indicated that over-expression of FTO is correlated with a positive prognosis, or that inhibiting FTO stimulates cancer progression. The RNA m6A methylation system is all about balance; and where there is imbalance - diseases like cancer seem to follow. This imbalance can be due to over-expression OR under-expression of FTO. Using Zantrene to target the over-expressing cancers only balances one side of the equation.

Here's a paper published last June that looked at FTO expression in PAAD (Pancreatic adenocarcinoma). The study found that m6A RNA modification levels were abnormally high in PAAD cells. Further investigation revealed that under-expressed FTO was the cause for this dysregulation (less FTO around to remove the m6A = higher levels of m6A). Further knockdown of FTO markedly induced proliferation of PAAD cell lines.

Here's another paper published last December that shows decreased expression of FTO in GBM (brain cancer) cells correlated with higher grades of gliomas and poorer clinical outcomes. Again, genetic knockdown of FTO promoted growth, migration, and invasion of cell lines in vitro and in vivo. Importantly, they note that work on FTO in GBM has been inconsistent in recent studies; referencing another paper that found that inhibiting FTO significantly suppressed progression of GBM cells.

Jianjun Chen's recent paper (COH 1.5) is a review of current research on FTO in cancer, and does actually acknowledge several cancer types where a high level of FTO may correlate with a positive outcome.



From all the research so far on FTO's role in cancer, it would seem that in some sub types - FTO itself can help to suppress cancer. It's also important to realize that the science of epitranscriptomics is still in its infancy. New papers will continue to contradict themselves at times until a comprehensive understanding is achieved, which could honestly take a decade or two.

The important thing for RAC shareholders to understand is that none of this is bad news at all. If we can prove that a drug works in the clinic, we don't need to wait for the comprehensive science to catch up. And eventually there may be a drug that can stimulate the expression of FTO in cancers that rely on FTO under expression (the GBM paper linked above looks at this). However from a investment perspective, Zantrene doesn't need to work in all cancers - it doesn't even need to work in every cancer that over expresses FTO (27 at last count). If Zantrene can make a meaningful difference in just one cancer type we'll all have made a very successful investment. If FTO inhibition plays out in the clinic the way the science has indicated time and time again - then Zantrene will likely make history.

And this doesn't even touch on Cardioprotection...